
CYTEK BIOSCIENCES INC
CTKBNASDAQTrading Snapshot
- Day Range
- $4.65 โ $4.75
- 52-Week Range
- $3.28 โ $6.18
- Volume
- $1.81B
- Avg Volume
- $2.39B
- Shares Outstanding
- 129.1M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $201M
- Last Q Revenue
- $48M
- P/E Ratio
- -7.6
- P/S Ratio
- 3.0x
- EPS (TTM)
- $-0.62
- Dividend Yield
- 0.00%
Why Investors Own CTKB
- โHigh-growth profile โ revenue up +29.6% YoY with expanding US Equity exposure.
- โHealthy economics โ 35% gross margin and 28% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CYTEK BIOSCIENCES INC
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cytek Biosciences, Inc.'s Q2 2026 earnings call

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsMark MeehanWenbin Jiang - President, CEO & Chairman...

Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Cytek Biosciences, Inc.

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Cytek Biosciences Inc (CTKB) delivers solid Q2 2026 results with 6% revenue growth, launches the industry-first Borealis 60-color system, and raises full-year guidance despite EMEA softness.

Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth. Revenue for the quarter ended June 30 was $48.1 mill

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?